This retrospective study introduces the concept of extended [177Lu]Lu-PSMA RLT in mCRPC patients responding to [177Lu]Lu-PSMA RLT but completing standard treatment of six cycles with high residual tumor load. This evidence concerns the gene FOLH1 and neoplasm.